Drugs / Fludeoxyglucose (18F) (FDG)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01146054 Background | Oct 2009 → Oct 2013 | malignant pancreatic neoplasm | Stanford University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fludeoxyglucose (18F) (FDG) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01146054 ↗ |
| Route | Intravenous | “FDG-PET/CT scan is used in treatment planning. Treatment with 18F-FDG is calculated per the needs of each patient and given at the instruction of the investigator; iv” NCT01146054 ↗ |